Evaxion A/S

EVAX · NASDAQ

$3.76+$0.05 (+1.35%)TodayMarket closed ·
Prev close $3.71

About EVAX

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees
46
Headquarters
Hoersholm
Listed
Feb 5, 2021
Sector
Health Care
Industry
Biotechnology
Website
evaxion.ai

Similar companies

Companies in the same industry as Evaxion A/S

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.